Cargando…
CRISPR/Cas9 for hepatitis B virus infection treatment
Hepatitis B virus (HBV) infection remains a global health challenge. Despite the availability of effective preventive vaccines, millions of people are at risk of cirrhosis and hepatocellular carcinoma. Current drug therapies inhibit viral replication, slow the progression of liver fibrosis and reduc...
Autores principales: | Cai, Bo, Chang, Shixue, Tian, Yuhan, Zhen, Shuai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10170306/ https://www.ncbi.nlm.nih.gov/pubmed/37249290 http://dx.doi.org/10.1002/iid3.866 |
Ejemplares similares
-
Targeting Hepatitis B Virus With CRISPR/Cas9
por: Seeger, Christoph, et al.
Publicado: (2014) -
The Application of the CRISPR/Cas9 System in the Treatment of Hepatitis B Liver Cancer
por: Lv, Wei, et al.
Publicado: (2021) -
CRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized mice
por: Stone, Daniel, et al.
Publicado: (2020) -
Removal of Integrated Hepatitis B Virus DNA Using CRISPR-Cas9
por: Li, Hao, et al.
Publicado: (2017) -
Depleting hepatitis B virus relaxed circular DNA is necessary for resolution of infection by CRISPR-Cas9
por: Kostyushev, Dmitry, et al.
Publicado: (2023)